News
CMT provides survival benefit in young HL patients
Combined modality therapy (CMT) can improve survival in young patients with early stage Hodgkin lymphoma (HL), according to research published in...
News
EC approves split dosing regimen for daratumumab
The European Commission (EC) has granted marketing authorization for a split dosing regimen for daratumumab (Darzalex®). The approval provides...
News
Potential treatment on the horizon for cold agglutinin disease
In a first-in-human trial, sutimlimab rapidly halted hemolysis, corrected anemia, precluded the need for transfusion, and caused no serious...
News
FDA approves first treatment for BPDCN
The U.S.
News
FDA approves ravulizumab for PNH
The U.S.
News
FDA approves calaspargase pegol-mknl for ALL
The U.S.
News
CHMP recommends treosulfan for allo-HSCT conditioning
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for treosulfan (Trecondi) as part...
News
CHMP backs lusutrombopag for severe thrombocytopenia
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for lusutrombopag to treat severe...
News
Long-acting interferon recommended for PV
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for ropeginterferon alfa-2b (...
News
CHMP backs dasatinib for kids with newly diagnosed ALL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
Health Canada approves new indication for daratumumab
Health Canada has approved a third indication for daratumumab (Darzalex®) in multiple myeloma (MM). The drug is now approved for use in...
News
CHMP recommends BV+AVD for Hodgkin lymphoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
Romiplostim now approved for children with ITP
The thrombopoietin receptor agonist romiplostim (NPlate®) is now approved by the U.S.
